Article
Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome.
PloS one - 1 Jan 2012
Hall Kathryn T, Lembo Anthony J, Kirsch Irving, Ziogas Dimitrios C, Douaiher Jeffrey, Jensen Karin B, Conboy Lisa A, Kelley John M, Kokkotou Efi, Kaptchuk Ted J
Abstract excerpt
Identifying patients who are potential placebo responders has major implications for clinical practice and trial design. Catechol-O-methyltransferase (COMT), an important enzyme in dopamine catabolism plays a key role in processes associated with the placebo effect such as reward, pain, memory and learning. We hypothesized that the COMT functional val158met polymorphism, was a predictor of placebo effects and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.